Impact of Comorbidities and Severity on Outcomes in Bronchiectasis Excerbations

ConditionBronchiectasis With Acute Exacerbation

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorSohag University

About this trial

Acute exacerbations of bronchiectasis are associated with variable outcomes depending on patient factors. Comorbidities such as COPD, diabetes, and cardiovascular disease, as well as disease severity scores, significantly influence hospitalization rates, length of stay, need for intensive care, and mortality. Understanding these associations helps in risk stratification, guiding management, and improving prognosis in affected patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults (≥18 years) admitted with a diagnosis of "Bronchiectasis with acute exacerbation". The bronchiectasis exacerbation is diagnosed based on deterioration in three or more of the following main symptoms for 48h at least: cough, sputum volume or sputum consistency, purulent sputum, breathlessness or exercise tolerance, fatigue or malaise, hemoptysis, and the requirement of a change in the bronchiectasis treatment as determined by a clinician.

Disqualifiers

Patients younger than 18 years of age. Patients who refuse participation or whose medical records lack informed consent (if applicable).

Trial population

The study population will include adult patients (≥18 years) diagnosed with bronchiectasis who are admitted to the hospital with acute exacerbations. Patients will be recruited from the Department of Chest Diseases at Sohag University Hospital (or your hospital name). All eligible patients during the study period will be included consecutively. Data regarding demographic characteristics, comorbidities, disease severity scores (BSI or FACED), and clinical outcomes will be collected and analyzed.

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

Observational assessment of comorbidities and disease severity
Other intervention
\> This study involves no active intervention. Data will be collected from patients with acute exacerbations of bronchiectasis to assess the impact of comorbidities and disease severity on clinical outcomes such as hospital stay, ICU admission, and mortality.

Treatment groups

100 Participants

are divided into 1 treatment group

Group A: adult bronchiectasis patient with acute excerbations1 intervention

Trial outcomes

Primary outcomes

Composite Clinical treatment failure during Bronchiectasis Exacerbation

composite clinical treatment failure,defined as the occurrence of any of the following events within 30 days of bronchiectasis exacerbation onset: 1.hospitalization related to the exacerbation 2.escalation or change of antibiotic therapy 3.Admission to the intensive care unit 4.Death from any cause

Time frame

30 days after exacerbation onset

Secondary outcomes

correlation between disease severity and clinical treatment failure

correlation between baseline bronchiectasis severity ,assessed using the bronchiectasis severity index(BSI), and clinical treatment failure during exacerbations.

Time frame

1 year

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sohag University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: